{
    "nct_id": "NCT05276492",
    "official_title": "Abiraterone Dose De-Escalation Study: A Prospective Study Evaluating Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.",
    "inclusion_criteria": "* Histologically or cytologically confirmed prostate cancer with plans to initiate abiraterone acetate\n* Have never received prior abiraterone or other androgen receptor modulators, including enzalutamide, apalutamide, or darolutamide.\n* Must have a baseline DHEA-S level of >20 mg/dL (in order to adequately assess DHEA-S response)\n* A minimum washout of 28 days for any other anticancer therapy other than medical or surgical castration, prior to first dose of study drug is required.\n* Any other radiotherapy or radionuclide require 28-day washout prior to first dose of study drug.\n* Denosumab or zoledronic acid are allowed.\n* Eastern Cooperative Oncology Group performance status ≤ 2 (Appendix A).\n* Participants must have normal hepatic function as defined by clinical lab values set by the study doctor/research team.\n* Ability to understand and the willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Therapy with other hormonal therapy, including any dose of megestrol acetate (Megace), finasteride (Proscar), dutasteride (Avodart), or any herbal product known to decrease Prostate-Specific Antigen levels or any systemic corticosteroid (other than prednisone ≤10mg/day) within 4 weeks prior to first dose of study drug.\n* Inability to swallow capsules or known gastrointestinal malabsorption.\n* Blood pressure that is not controlled despite > 2 oral agents (SBP >160 and DBP >90 documented during the screening period with no subsequent blood pressure readings <160/100).\n* Serum K+ < 3.5 mmoL/L. Patients with a K+ < 3.5 mmoL/L are required to have a documented subsequent K+ >3.5 prior to enrollment to be eligible.\n* Serious intercurrent infections or non-malignant medical illnesses that are uncontrolled.\n* Active psychiatric illness/social situations that would limit compliance with protocol requirements.\n* Serious heart issues/congestive heart failure as assessed by New York Heart Association's definition of class II, class III, or IV congestive heart failure.\n* Taking other medications or drugs with strong inhibitors or inducers of CYP3A4 (See Section 8.12 below for list of strong inhibitor or inducers) due to concerning possible drug-drug interactions with abiraterone.",
    "miscellaneous_criteria": ""
}